| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $166,101,178 ) (Continued on the next page) |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 000 | 20 | NIH | 11/30/2024 | $500,000 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | CoVPN 3006 - A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine | 004 | 20 | NIH | 4/18/2025 | $7,000,000 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 002 | 20 | NIH | 4/15/2025 | $4,000,000 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | CoVPN 3006 - A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine | 004 | 20 | NIH | 4/18/2025 | $6,924,806 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | CoVPN 3006 - A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine | 000 | 20 | NIH | 12/4/2024 | $9,176,243 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | CoVPN 3006 - A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine | 000 | 20 | NIH | 12/4/2024 | $6,924,807 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 002 | 20 | NIH | 4/15/2025 | $7,793,640 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 002 | 20 | NIH | 4/15/2025 | $250,000 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | P01CA078902 | Preventing Relapse After Non-myeloablative Stem Cell Transplantation: The Final Challenge | 000 | 27 | NIH | 4/25/2025 | $1,867,421 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | P30CA015704 | Cancer Center Support Grant | 007 | 50 | NIH | 5/1/2025 | $76,287 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | P30CA015704 | Cancer Center Support Grant | 007 | 50 | NIH | 5/1/2025 | $4,057,268 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | P30CA015704 | Cancer Center Support Grant | 007 | 50 | NIH | 5/1/2025 | $190,824 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | P30CA015704 | Cancer Center Support Grant | 001 | 50 | NIH | 4/8/2025 | $0 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | P30CA015704 | Cancer Center Support Grant | 000 | 50 | NIH | 3/14/2025 | $9,457,233 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | P30CA015704 | Cancer Center Support Grant | 002 | 50 | NIH | 4/16/2025 | $250,000 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | P30CA015704 | Cancer Center Support Grant | 003 | 50 | NIH | 4/21/2025 | $214,709 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U01CA214057 | Developing CVD prediction models for women with early stage breast cancer | 001 | 5 | NIH | 1/28/2025 | $0 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U01CA214057 | Developing CVD prediction models for women with early stage breast cancer | 000 | 5 | NIH | 1/17/2025 | $777,704 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI179712 | Metabolite- and cytokine-mediated signals interact to control human CD8 T cell responses in tissues | 000 | 1 | NIH | 1/17/2025 | $857,346 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UG1CA287013 | Statistics and Data Management Center (SDMC) for the NCI Cancer Screening Research Network (CSRN) | 000 | 2 | NIH | 1/1/2025 | $1,313,116 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI175535 | Defining Protective CMV Immunity after Transplantation | 000 | 3 | NIH | 1/23/2025 | $750,866 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AR045203 | D4Z4 Coding Transcripts and FSHD | 000 | 26 | NIH | 12/18/2024 | $514,273 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R21AI178255 | Viral gene drive as a novel curative therapy for HSV infection | 000 | 2 | NIH | 12/13/2024 | $247,126 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA295090 | MAPK-driven kinetochore stress in cancer | 000 | 1 | NIH | 3/7/2025 | $652,799 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UH3DA057032 | ACT on Vaping: Digital Therapeutic for Young Adult Vaping Cessation | 001 | 3 | NIH | 5/8/2025 | $89,732 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UH3DA057032 | ACT on Vaping: Digital Therapeutic for Young Adult Vaping Cessation | 000 | 3 | NIH | 12/12/2024 | $772,015 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA297681 | Statistical Methods for Precision Prevention | 000 | 1 | NIH | 12/4/2024 | $505,613 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | F32HD113384 | Developmental mechanisms specifying vagal innervation of organ targets | 000 | 2 | NIH | 12/9/2024 | $76,756 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI179457 | Early intervention with anti-proliferative therapy close to ART initiation to limit long-term SIV persistence | 001 | 2 | NIH | 4/16/2025 | $846,498 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R13AI189265 | Flow Cytometry Workshops in Africa | 000 | 1 | NIH | 12/1/2024 | $25,000 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM140823 | Mechanisms of transcriptional regulation and transcription factor specificity | 001 | 5 | NIH | 2/20/2025 | $1,009,413 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U19AI174242 | Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs | 005 | 3 | NIH | 3/24/2025 | $0 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U19AI174242 | Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs | 004 | 3 | NIH | 3/24/2025 | $0 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U19AI174242 | Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs | 003 | 3 | NIH | 1/15/2025 | $163,398 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U19AI174242 | Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs | 003 | 3 | NIH | 1/15/2025 | -$163,398 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U19AI174242 | Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs | 002 | 3 | NIH | 12/12/2024 | $163,398 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U19AI174242 | Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs | 001 | 3 | NIH | 12/6/2024 | $1,415,922 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U01CA295226 | Optimizing pre-analytical variables for reliable mass spectrometry-based quantification of immunomodulatory proteins in cerebrospinal fluid in pediatric neuro-oncology trials | 000 | 1 | NIH | 3/19/2025 | $440,171 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM144128 | Data analysis tools for leveraging massive public data to improve hypothesis-driven research | 001 | 5 | NIH | 4/4/2025 | $430,679 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R37CA230617 | Hormone signaling and translation control in advanced prostate cancer | 001 | 8 | NIH | 11/1/2024 | $390,547 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA287476 | Interrogating a novel axis of tumor suppression in small cell lung cancer | 000 | 1 | NIH | 11/14/2024 | $548,915 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM119835 | Regulation of Protein Synthesis by Synonymous Codon Usage | 001 | 11 | NIH | 5/5/2025 | $425,872 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01MH132500 | Evaluating a Multilevel Communication Campaign to Increase HIV Vaccine Trial Enrollment | 001 | 3 | NIH | 4/7/2025 | $0 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01MH132500 | Evaluating a Multilevel Communication Campaign to Increase HIV Vaccine Trial Enrollment | 001 | 3 | NIH | 4/7/2025 | $0 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01MH132500 | Evaluating a Multilevel Communication Campaign to Increase HIV Vaccine Trial Enrollment | 000 | 3 | NIH | 3/26/2025 | $177,333 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01MH132500 | Evaluating a Multilevel Communication Campaign to Increase HIV Vaccine Trial Enrollment | 000 | 3 | NIH | 3/26/2025 | $356,764 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 000 | 20 | NIH | 11/7/2024 | $141,120 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 000 | 20 | NIH | 11/7/2024 | $699,159 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI177095 | Guiding the maturation of anti-CD4-BS bnAbs through sequential heterologous Env immunization | 001 | 2 | NIH | 2/28/2025 | $873,050 |
|
